keyword
MENU ▼
Read by QxMD icon Read
search

Verifynow

keyword
https://www.readbyqxmd.com/read/29782255/-high-on-treatment-platelet-reactivity-determinants-on-dual-antiplatelet-therapy-in-patients-with-ischemic-heart-disease-before-elective-percutaneous-coronary-intervention
#1
E Z Golukhova, M V Grigoryan, M N Ryabinina, N I Bulaeva
OBJECTIVE: to determine impact of different laboratory and genetic factors on high on-treatment platelet reactivity (HOPR) during dual antiplatelet therapy (DAPT). METHODS: We included in this study 94 patients with stable ischemic heart disease (mean age 59±9.67 years). All patients underwent elective PCI with implantation of drug eluting stents at the background of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. Platelet reactivity was assessed using light transmission aggregometry with 5 μmol/L ADP (LTA 5ADP) and VerifyNow assay before PCI...
April 2018: Kardiologiia
https://www.readbyqxmd.com/read/29743380/tailored-adjunctive-cilostazol-therapy-based-on-cyp2c19-genotyping-in-patients-with-acute-myocardial-infarction-the-caldera-gene-study
#2
Koichi Kaikita, Hiromi Yoshimura, Masanobu Ishii, Takashi Kudoh, Yoshihiro Yamada, Eiichiro Yamamoto, Yasuhiro Izumiya, Sunao Kojima, Hideki Shimomura, Ryusuke Tsunoda, Kunihiko Matsui, Hisao Ogawa, Kenichi Tsujita
BACKGROUND: Patients with reduced-function CYP2C19 genotypes on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel show higher clinical risk for acute myocardial infarction (AMI). We investigated the effect of CYP2C19 genotype-tailored adjunctive cilostazol therapy on treatment of AMI.Methods and Results:The study group of 138 patients with suspected AMI were screened for CYP2C19 genotype immediately after percutaneous coronary intervention (PCI) using a SPARTAN RX point-of-care device...
May 8, 2018: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/29731189/potent-effect-of-prasugrel-on-acute-phase-resolution-of-intra-stent-athero-thrombotic-burden-after-percutaneous-intervention-to-acute-coronary-syndrome
#3
Yoshiro Tsukiyama, Amane Kozuki, Toshiro Shinke, Hiromasa Otake, Yoichi Kijima, Tomoya Masano, Ryoji Nagoshi, Hiroyuki Shibata, Ryo Takeshige, Ken-Ichi Yanaka, Junya Shite, Ken-Ichi Hirata
BACKGROUND: Recent studies suggested protruding thrombus and atheroma after stent placement could be a substrate for subsequent adverse ischemic events. Although protruded atherothrombotic burden can be assessed as intra-stent tissue (IST) by optical coherence tomography (OCT), the effects of potent antiplatelet therapy on the acute phase resolution of IST in patients with acute coronary syndrome (ACS) was unknown. METHODS: Ninety-six consecutive ACS patients with multi-vessel disease were enrolled in this prospective registry...
May 3, 2018: Journal of Cardiology
https://www.readbyqxmd.com/read/29719963/point-of-care-tests-verifynow-p2y12-and-innovance-pfa-p2y-compared-to-light-transmittance-aggregometry-after-fibrinolysis
#4
Vincent Roule, Pierre Ardouin, Yohan Repessé, Agnès Le Querrec, Katrien Blanchart, Adrien Lemaitre, Rémi Sabatier, Annie Borel-Derlon, Farzin Beygui
Detection of high on-treatment platelet reactivity (HPR) by point-of-care tests has not been validated after successful fibrinolysis for ST-elevation myocardial infarction. We assessed the validity of the point-of-care VerifyNow P2Y12 (VN) and INNOVANCE PFA P2Y (PFA) tests on HPR compared to light transmittance aggregometry (LTA) in these patients. The HPR was identified in 10 (34.5%) patients, 15 (51.7%) patients, and 14 (50%) patients using LTA, VN, and PFA, respectively. Discrepancies were observed between the tests despite significant correlations between platelet reactivity measures by LTA and VN ( r = 0...
January 1, 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/29608747/pharmacy-mediated-antiplatelet-management-protocol-compared-to-one-time-platelet-function-testing-prior-to-pipeline-embolization-of-cerebral-aneurysms-a-propensity-score-matched-cohort-study
#5
Christoph J Griessenauer, Abhi Jain, Alejandro Enriquez-Marulanda, Raghav Gupta, Nimer Adeeb, Justin M Moore, Stacey A Grassi, Shamsher S Dalal, Christopher S Ogilvy, Ajith J Thomas, Clemens M Schirmer
BACKGROUND: There is ongoing controversy regarding the optimal antiplatelet regimen, and extent or even need for platelet function testing surrounding Pipeline flow diverter (Medtronic Inc, Dublin, Ireland) embolization of cerebral aneurysms. OBJECTIVE: To compare a unique pharmacy-mediated antiplatelet medication management protocol to a 1-time platelet function testing strategy prior to Pipeline placement. METHODS: A retrospective review of patients with cerebral aneurysms who underwent Pipeline embolization at 2 academic institutions was performed...
March 27, 2018: Neurosurgery
https://www.readbyqxmd.com/read/29571721/relation-of-platelet-indexes-to-platelet-reactivity-and-periprocedural-myocardial-infarction-in-patients-who-underwent-percutaneous-coronary-angioplasty
#6
Elisabetta Ricottini, Fabio Mangiacapra, Annunziata Nusca, Rosetta Melfi, Ilaria Cavallari, Marco Miglionico, Paolo Gallo, Paolo Pozzilli, Germano Di Sciascio
No comprehensive data are available on the role of platelet indexes (PI) in the periprocedural risk stratification of patients who underwent percutaneous coronary intervention (PCI). The aim of this study was to investigate the relation of PI to platelet reactivity (PR) and periprocedural myocardial infarction (PMI) in patients receiving PCI. A total of 502 PCI patients had preprocedural measurement of PI and PR, the latter assessed by VerifyNow P2Y12 assay. Study end points were incidence of PMI and high platelet reactivity (HPR) according to tertiles of PI and evaluation of PI in HPR patients...
February 5, 2018: American Journal of Cardiology
https://www.readbyqxmd.com/read/29552932/optimal-platelet-function-test-for-in-stent-tissue-protrusion-following-carotid-artery-stenting
#7
Masanori Tsujimoto, Yukiko Enomoto, Masafumi Miyai, Yusuke Egashira, Toru Iwama
Purpose To determine the best platelet function test for in-stent tissue protrusion following carotid artery stenting (CAS). Methods Patients who underwent CAS were recruited prospectively in this observational study. Combination of aspirin 100 mg/day and clopidogrel 75 mg/day was administered for a minimum of 7 days prior to procedure. Platelet aggregation was measured by light transmittance aggregometry (LTA) following stimulation by adenosine diphosphate (ADP), collagen, and thrombin receptor activating peptide (TRAP) and by the point of care assay, VerifyNow which measures aspirin and thienopyridine reaction units...
May 2018: Journal of International Medical Research
https://www.readbyqxmd.com/read/29526833/pharmacodynamic-effects-of-switching-from-ticagrelor-to-clopidogrel-in-patients-with-coronary-artery-disease-results-of-the-swap-switching-antiplatelet-therapy-4-study
#8
Francesco Franchi, Fabiana Rollini, Jose Rivas Rios, Andrea Rivas, Malhar Agarwal, Megha Kureti, Deepa Nagaraju, Mustafa Wali, Zubair Shaikh, Maryuri Briceno, Ahmed Nawaz, Jae Youn Moon, Latonya Been, Siva Suryadevara, Daniel Soffer, Martin M Zenni, Theodore A Bass, Dominick J Angiolillo
BACKGROUND : Switching between different classes of P2Y12 inhibitors, including de-escalation from ticagrelor to clopidogrel, commonly occurs in clinical practice. However, the pharmacodynamic profiles of this strategy have been poorly explored. METHODS : This was a prospective, randomized, open-label study conducted in patients on maintenance dosing (MD) of aspirin (81 mg/d) and clopidogrel (75 mg/d). After a 7-day run-in with ticagrelor (180 mg loading dose [LD] followed by 90 mg twice daily MD), patients (n=80) were randomized into 1 of 4 groups: group A, clopidogrel 600 mg LD 24 hours after the last MD of ticagrelor (C-600 mg-24h); group B, clopidogrel 600 mg LD 12 hours after the last MD of ticagrelor (C-600 mg-12h); group C, clopidogrel 75 mg/d MD 24 hours after the last MD of ticagrelor (C-75 mg-24h); and group D, ticagrelor 90 mg twice daily MD (T-90 mg twice daily)...
March 11, 2018: Circulation
https://www.readbyqxmd.com/read/29526765/pharmacometabolomics-analysis-of-plasma-to-phenotype-clopidogrel-high-on-treatment-platelets-reactivity-in-coronary-artery-disease-patients
#9
Arwa M Amin, Lim Sheau Chin, Chin-Hoe Teh, Hamza Mostafa, Dzul Azri Mohamed Noor, Muhamad Ali S K Abdul Kader, Yuen Kah Hay, Baharudin Ibrahim
Dual antiplatelet therapy (DAPT) of clopidogrel and aspirin is crucial for coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI). However, some patients may endure clopidogrel high on treatment platelets reactivity (HTPR) which may cause thromboembolic events. Clopidogrel HTPR is multifactorial with some genetic and non-genetic factors contributing to it. We aimed to use nuclear magnetic resonance (1 H NMR) pharmacometabolomics analysis of plasma to investigate this multifactorial and identify metabolic phenotypes and pathways associated with clopidogrel HTPR...
May 30, 2018: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29526063/clopidogrel-response-variability-in-unruptured-intracranial-aneurysm-patients-treated-with-stent-assisted-endovascular-coil-embolization-is-follow-up-clopidogrel-response-test-necessary
#10
Min Soo Kim, Eun Suk Park, Jun Bum Park, In Uk Lyo, Hong Bo Sim, Soon Chan Kwon
OBJECTIVE: The purpose of this study was to analyze the variability of clopidogrel responses according to duration of a clopidogrel drug regimen after stent-assisted coil embolization (SAC), and to determine the correlation between the variability of clopidogrel responses and thromboembolic or hemorrhagic complications. METHODS: A total of 47 patients who underwent SAC procedures to treat unruptured intracranial aneurysms were enrolled in the study. Preoperatively, patients received more than seven days of aspirin (100 mg) and clopidogrel (75 mg), daily...
March 2018: Journal of Korean Neurosurgical Society
https://www.readbyqxmd.com/read/29482349/low-levels-of-high-density-lipoprotein-cholesterol-are-linked-to-impaired-clopidogrel-mediated-platelet-inhibition
#11
Patricia P Wadowski, Silvia Lee, Christoph W Kopp, Renate Koppensteiner, Simon Panzer, Thomas Gremmel
Low high-density lipoprotein cholesterol (HDL-C) levels are an independent predictor of ischemic events in patients with atherosclerotic cardiovascular disease. This may in part be due to decreased clopidogrel-mediated platelet inhibition in patients with low HDL-C. We investigated the association of HDL-C with on-treatment platelet reactivity to adenosine diphosphate (ADP) in 314 patients on dual antiplatelet therapy with clopidogrel and aspirin undergoing angioplasty and stenting. Platelet P-selectin expression was assessed by flow cytometry, and platelet aggregation was determined by the VerifyNow P2Y12 assay and the Impact-R...
January 1, 2018: Angiology
https://www.readbyqxmd.com/read/29461906/how-does-measurement-of-platelet-p-selectin-compare-with-other-methods-of-measuring-platelet-function-as-a-means-of-determining-the-effectiveness-of-antiplatelet-therapy
#12
Susan C Fox, Jane A May, Natalia Dovlatova, Jackie R Glenn, Andrew Johnson, Ann E White, Ashwin Radhakrishnan, Stan Heptinstall
Measurement of P-selectin on activated platelets as a means of measuring platelet function utilizing the technology described here has the advantage of not requiring immediate access to specialist equipment and expertise. Blood samples are activated, fixed, stored, and transported to a central laboratory for flow cytometric analysis. Here we have compared P-selectin with other more traditional approaches to measuring platelet function in blood and/or platelet-rich plasma (PRP) from patients with acute coronary syndromes on treatment for at least 1 month with either aspirin and clopidogrel or aspirin with prasugrel...
February 20, 2018: Platelets
https://www.readbyqxmd.com/read/29450765/impact-of-platelet-reactivity-on-5-year-clinical-outcomes-following-percutaneous-coronary-intervention-a-landmark-analysis
#13
Fabio Mangiacapra, Iginio Colaiori, Elisabetta Ricottini, Antonio Creta, Giuseppe Di Gioia, Ilaria Cavallari, Edoardo Bressi, Marialessia Capuano, Emanuele Barbato, Germano Di Sciascio
We investigated the impact of suboptimal platelet reactivity on clinical outcomes after percutaneous coronary intervention (PCI). We enrolled 500 patients with stable coronary artery disease undergoing elective PCI. Platelet reactivity was measured before PCI using the VerifyNow P2Y12 assay. Primary endpoint was the incidence of ischemic or bleeding events at 1 month and 5 years. Patients with high platelet reactivity (HPR) showed significantly higher rates of ischemic events both during the 1st month after PCI (HR 2...
May 2018: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/29447774/percutaneous-coronary-intervention-of-lesions-with-in-stent-restenosis-a-report-from-the-adapt-des-study
#14
Björn Redfors, Philippe Généreux, Bernhard Witzenbichler, Akiko Maehara, Giora Weisz, Thomas McAndrew, Roxana Mehran, Ajay J Kirtane, Gregg W Stone
BACKGROUND: There is a paucity of data from large contemporary cohorts of patients with in-stent restenosis (ISR) treated with drug-eluting stents (DESs), and no studies have examined the impact of high platelet reactivity (HPR) on the occurrence of ischemic events after ISR percutaneous coronary intervention (PCI) with DESs. We sought to report outcomes after PCI of ISR lesions and its association with HPR. METHODS: Patients in the prospective, multicenter ADAPT-DES study were stratified according to whether they had ISR versus non-ISR PCI...
March 2018: American Heart Journal
https://www.readbyqxmd.com/read/29443445/aspirin-withdrawal-in-patients-treated-with-ticagrelor-presenting-with-non-st-elevation-myocardial-infarction
#15
R Beigel, I Mazin, E Koifman, M Shechter, H Pres, N Shlomo, N Rosenberg, E Asher, S Matetzky
Essentials Strong P2Y12 blockade may cause platelet inhibition that is only minimally enhanced by aspirin. We evaluated aspirin withdrawal on platelet reactivity in ticagrelor treated patients. Aspirin withdrawal resulted in increased platelet reactivity to arachidonic acid. Aspirin withdrawal caused little difference in adenosine diphosphate-induced platelet aggregation. SUMMARY: Background Recent studies have shown that the thromboxane A2 -dependent pathway is dependent on the ADP-P2Y12 pathway, and that strong P2Y12 receptor blockade alone causes inhibition of platelet aggregation that is minimally enhanced by aspirin...
April 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29422165/evaluating-the-effectiveness-of-pre-operative-platelet-inhibition-testing-to-reduce-costs-and-pre-operative-length-of-stay
#16
Jennifer Bobbitt, Kathleen Petro, Michael Martin
This was a retrospective study to assess the effectiveness of Society of Thoracic Surgeons (STS) Guidelines in reducing resource utilization at Washington Adventist Hospital, Takoma Park, Maryland. Pre and post operative stay (days), platelets and other blood product use, along with hospital costs were compared in elective Cardiac Surgical patients receiving P2Y12 inhibitors in the year prior to and year following the implementation of the STS guidelines of preoperative monitoring of platelet inhibition with VerifyNow...
February 2018: Applied Nursing Research: ANR
https://www.readbyqxmd.com/read/29411531/aspirin-and-clopidogrel-high-on-treatment-platelet-reactivity-and-genetic-predictors-in-peripheral-arterial-disease
#17
Khung-Keong Yeo, Ehrin J Armstrong, Javier E López, Debbie C Chen, Gregory G Westin, Chin-Shang Li, David Anderson, Amy Hua, Anil Singapuri, Ezra A Amsterdam, Nipavan Chiamvimonvat, John R Laird
OBJECTIVES: Our aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on-treatment platelet reactivity (HoTPR), and associated adverse cardiovascular outcomes in patients with peripheral arterial disease (PAD). BACKGROUND: The association of aspirin and clopidogrel HoTPR with outcomes in PAD remains unclear. METHODS: This is a prospective cohort study of patients with angiographically documented PAD involving carotid and lower extremity arteries...
February 7, 2018: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29408797/effect-of-cilostazol-on-platelet-reactivity-among-patients-with-peripheral-artery-disease-on-clopidogrel-therapy
#18
Dagmar F Hernandez-Suarez, Hector Núñez-Medina, Stuart A Scott, Angel Lopez-Candales, Jose M Wiley, Mario J Garcia, Kyle Melin, Karid Nieves-Borrero, Christina Rodriguez-Ruiz, Lorraine Marshall, Jorge Duconge
BACKGROUND: Antiplatelet therapy with clopidogrel is recommended to reduce cardiovascular events in patients with peripheral artery disease (PAD); however, clopidogrel efficacy has not been adequately studied in this patient population. Therefore, we aimed to determine the effects of cilostazol therapy on platelet reactivity among PAD patients on clopidogrel. METHODS: We performed a cross-sectional pilot study of 46 Puerto Rican patients diagnosed with PAD. The cohort was divided based on use of clopidogrel and cilostazol (n=24) or clopidogrel alone (n=22)...
March 28, 2018: Drug Metabolism and Personalized Therapy
https://www.readbyqxmd.com/read/29370383/circadian-variation-of-ticagrelor-induced-platelet-inhibition-in-healthy-adulty
#19
Stephane Fournier, Florine Guenat, Anne Fournier, Lorenzo Alberio, Olivier Bonny, Debora Bertaggia Calderara, Daniel Bardy, Nathalie Lauriers, Brahim Harbaoui, Pierre Monney, Patrizio Pascale, Eric Eeckhout, Olivier Muller
Aims: The circadian variation of platelet aggregation is well demonstrated. However, whether this has an impact on antiplatelet inhibition therapy is poorly documented. We aimed to observe whether ticagrelor-induced platelet inhibition follows a circadian rhythm. Methods and Results: The study included 25 healthy volunteers (11 female;14 male). Blood samples were collected every 4 hours. Ticagrelor was added in vitro at a concentration that provided 50% inhibition of the maximum response using the VerifyNow System Platelet Reactivity Test® thus avoiding any bias induced by circadian gastro-intestinal absorption...
January 23, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29354177/the-influence-of-adding-tomato-extract-and-acetylsalicylic-acid-to-hypotensive-therapy-on-the-daily-blood-pressure-profiles-of-patients-with-arterial-hypertension-and-high-cardiovascular-risk
#20
Angelika N Osińska, Beata Begier-Krasińska, Piotr Rzymski, Aleksandra Krasińska, Andrzej Tykarski, Zbigniew Krasiński
Introduction: Arterial hypertension (HT) is one of the most common diseases around the world and constitutes a significant medical, social, and economic problem. Lifestyle changes, including adequate fruit and vegetable consumption, play an important role in controlling blood pressure (BP) and other cardiovascular risk factors. Aim: To compare the influence of adding acetylsalicylic acid (ASA) or standardized tomato extract (STE) to standard hypotensive therapy on the values of arterial pressure and the daily blood pressure profiles of patients with hypertension and high cardiovascular risk...
December 2017: Kardiochirurgia i Torakochirurgia Polska, Polish Journal of Cardio-Thoracic Surgery
keyword
keyword
39783
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"